The Business Research Company’s Bi-Specific MAbs Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, August 4, 2021 /EINPresswire.com/ -- The global bi-specific MAbs market is expected to grow from $2.93 billion in 2020 to $3.75 billion in 2021 at a compound annual growth rate (CAGR) of 28%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $10 billion in 2025 at a continued CAGR of 28%. The increasing prevalence of cancer and other chronic diseases is anticipated to propel the demand for the bispecific monoclonal antibodies market to treat these diseases effectively.

Bi-specific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bi-specific monoclonal antibodies are considered to be more effective than monoclonal antibodies (MAbs) as these target two or more tumor antigens on cells to disrupt cancer progression.

Read More On The Global Bi-Specific MAbs Market Report:
https://www.thebusinessresearchcompany.com/report/bi-specific-mabs-market-global-report-2020-30-covid-19-growth-and-change

The major players covered in the bispecific antibody therapeutics market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company, Ltd., Abbott, AstraZeneca, Eli Lilly, Merck & Co. Inc., Amgen Inc., Pfizer Inc., GlaxoSmithKline plc, Roche, Sanofi, Genentech, Immunomedics, Chugai Pharmaceutical, EMD Serono, Emergent BioSolutions, Jounce Therapeutics, MarcoGenics, Merus, Neovii Biotech, NovImmune SA, OncoMed Pharmaceuticals, Pieris, Regeneron Pharmaceuticals.

Companies in the bi-specific MAbs market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging Bi-specific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment.

TBRC’s global bi-specific MAbs market report is segmented by type into catumaxomab (removab), blinatumomab, duligotumab, SAR 156597; by product type into in vivo, in vitro; by indication into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, others; by end-use into hospitals, research institutes, others.

Bi-Specific MAbs Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides bi-specific MAbs market overview, forecast bi-specific MAbs market size and growth for the whole market, bi-specific MAbs market segments, and geographies, bi-specific MAbs market trends, bi-specific MAbs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Bi-Specific MAbs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Kidney Cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid Cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
(https://www.thebusinessresearchcompany.com/report/oncology-drugs-market)

Pharmaceutical Drugs Market - By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
(https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-market)

CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
(https://www.thebusinessresearchcompany.com/report/car-t-therapy-market)

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Email: info@tbrc.info
Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on Twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn